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ABSTRACT: BaP1, a zinc-dependent endopeptidase belonging to the P-I class of snake venom metalloprotei-
nases, exerts multiple tissue-damaging activities, leading to hemorrhage, myonecrosis, dermonecrosis,
blistering, and edema. Interestingly, this metalloproteinase shows a high degree of structural homology with
the catalytic domain of human adamalysins andmatrix metalloproteinases, especially at the strictly conserved
zinc binding motif and the so-called Met turn. This highlights BaP1 as an interesting model concerning
inhibitor design for several medicinally important metalloproteinases, such as tumor necrosis factor R
converting enzyme. Here, we report the first crystal structure of BaP1 complexed with a peptidomimetic
inhibitor. Suitable crystals were obtained at four different pH values (4.6, 6.5, 7.5, and 8.0), and four high-
resolution structures (1.46, 1.14, 1.08, and 1.05 A˚) were established. These structures and the detailed analysis
of the structure-activity relationship of the bound inhibitor form a basis for the design of potent BaP1
inhibitors. The latter can be used for the treatment of local pathological effects caused by snake bites, mainly
due tometalloproteinases such as BaP1. Besides, the high-resolution structure is an excellent starting point for
the rational development of inhibitors for human metalloproteinases. The finding of a flexible loop region
may have a great impact on further studies as to date little is known about the structural dependencies of the
hemorrhagic activity of snake venom metalloproteinases.
Metalloendopeptidases (MEPs)1 from snake venoms [snake
venom metalloproteinases (SVMPs)] and ADAMs (a disintegrin
and metalloproteinase domain-containing enzymes) constitute
the reprolysin subfamily of the “metzincin” superfamily of zinc-
dependent metalloendopeptidases (1). Metzincins have two char-
acteristic features: the conserved zinc binding motif
HEbxHxbGbxHD (b, bulky hydrophobic residue; x, any residue)
that contains the catalytic glutamate residue and the so-called
Met turn, a methionine-containing 1,4-β-turn that plays an
important structural role near the active site (2-6). A reaction
mechanism in which the catalytic glutamate polarizes a zinc-
bound water molecule, thereby increasing its nucleophilic char-
acter, has been proposed. The polarized water subsequently
cleaves the substrate peptide bond in an addition-elimination
mechanism (3, 4, 7). Efforts are being made to investigate the pH
dependency of the proteolytic activity of SVMPs and other
metzincins, generally known to be higher in the neutral to basic
range (4). It was assumed that at a lower pH, the capacity of the
glutamate residue to polarize the catalytic water molecule is
diminished, preventing nucleophilic attack on the scissile peptide
bond.
After the first ADAM was discovered in guinea pig sperm, it
became clear that these enzymes possess important biological
properties and that the catalytic domains ofADAMsandSVMPs
are structurally very similar, particularly in the fold and the
arrangement of the active site cleft (3, 8-10). ADAMs have been
implicated in a set of diseases, i.e., diabetes, Alzheimer’s disease,
cardiac hypertrophy, cancer, rheumatoid arthritis, Crohn’s dis-
ease, and microbial infections (8, 11). Especially ADAM-17, also
known as TACE (tumor necrosis factor R converting enzyme),
deserves high interest as a promising medicinal target, as it
cleaves the membrane-bound precursor of tumor necrosis factor
R (TNF-R) to its soluble form (12, 13).
Every year more than 2.6 million people worldwide are
envenomed by snake bites, leading to more than 125000
deaths (14). Snake venoms are a complex mixture of proteins,
inorganic compounds, and metal ions (4). While systemic patho-
physiological alterations are readily avoided by timely adminis-
tration of antivenoms, local pathological effects are difficult to
neutralize, primarily because of the very rapid development of
these lesions (15). The main venom components responsible for
‡Coordinates and structure factors of the BaP1 3 inhibitor complex
have been deposited at the Protein Data Bank as entries 2W12, 2W13,
2W14, and 2W15.
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local pathology are myotoxic phospholipases A2 and metallo-
proteinases (16). In particular, the zinc-dependent SVMPs cause
hemorrhagic effects, myonecrosis, skin damage, edema, and
other reactions associated with inflammation as well as relevant
hemostatic and hematological alterations (17-19). Several
SVMPs have been characterized, and they are presently categor-
ized into three main classes (P-I, P-II, and P-III) based on their
different sizes and domain structures (1, 17, 20). One of these
SVMPs is BaP1, isolated from the venom of Bothrops asper, the
medically most important snake in Central America (21). It is a
22.7 kDa P-I SVMP exhibiting high proteolytic activity and
locally inducing hemorrhage, inflammation, and moderate myo-
necrosis. After intramuscular injection, it causes formation of
blisters, infiltration of leukocytes, and the release of cytokines,
including interleukin-1 and TNF-R (22, 23). The maximum
proteolytic activity of BaP1 in vitro occurs at pH 8.0, whereas
the physiological reaction conditions are around pH 7.4 (18).
One of the main features of viperid snake venom is the ability
to induce hemorrhage in local tissue, which is mainly due to
SVMPs (16, 17, 23). The intensity of hemorrhagic activity varies
greatly between the different classes of SVMPs, with the P-III
class usually being more hemorrhagic than the P-I class. This was
explained by the existence of additional domains, better access to
physiologically relevant targets inmicrovessels, and the abillity of
P-III SVMPs to inhibit collagen-induced platelet aggrega-
tion (24). However, there are also large differences in hemor-
rhagic activity within the P-I class of SVMPs, indicating that
structural features in the metalloproteinase domain itself may
play a role. Comparisons of several SVMPs with different
hemorrhagic potential have shown that there are conspicuous
structural variations in a loop region surrounding the active
site (24, 25). Recently, a bioinformatics study involving com-
parative surface analysis of several hemorrhagic and nonhemor-
rhagic SVMPs (P-I as well as P-III) revealed small differences in
molecular surface area within the P-I SVMPs that correlate with
hemorrhagic potential (26).
Although long appreciated in traditional practice, the poten-
tial of snake venoms and their components as a basis for drug
design and novel therapies has only recently been recognized by
modern medicine (27, 28). One of the first examples was the
development of synthetic inhibitors for angiotensin converting
enzyme using the structure of an oligopeptide from Bothrops
jararaca venom (29). Structural similarities between snake venom
proteins and human enzymes offer intriguing possibilities for the
development of inhibiting compounds. Accordingly, several
SVMP 3 inhibitor/substrate complexes have already been used
to investigate structure-activity relationships and to design
inhibitors for metalloproteinases (4, 30-35). Different zinc
binding moieties are known that can be used to guide these
inhibitors to the active site of metzincins. Among these, hydro-
xamate derivatives with peptidomimetic scaffolds exhibit an
especially high potential and are therefore of great interest for
the development of small molecule inhibitors for SVMPs,
ADAMs, and MMPs (36).
The overall structure of BaP1 [Protein Data Bank (PDB) entry
1ND1] (24) is very similar to the seven other structurally known
P-I SVMPs (7, 25, 34, 35, 37-40). It consists of a major N-
terminal subdomain (residues 1-152) and a minor C-terminal
subdomain (residues 153-202) which flank the shallow active
site cleft. The major domain adopts an R/β-fold containing
four R-helices (R1, R2, R3, and R4) and a five stranded β-sheet
(β1, β2, β3, β4, and β5).All strands are parallel except antiparallel
strand β4. The minor domain consists of one R-helix (R5) and
various loops, including the conserved Met turn.
Here, the first crystal structure of the SVMP BaP1 in complex
with a metalloproteinase inhibitor, primarily used as a TACE
inhibitor, is reported. To structurally show the dependency of the
proteolytic activity on the pH value, the crystallization procedure
was carried out at different pH values. Suitable crystals were
obtained at four different pH values (4.6, 6.5, 7.5, and 8.0), and
four high-resolution structures (1.46, 1.14, 1.08, and 1.05 A˚) were
established. This structural analysis offers new insight into the
pH dependency of inhibitor binding as well as important
structural and functional aspects of a flexible loop region linked
to hemorrhagic activity. In addition, this study improves our
understanding of metalloproteinases and forms a solid platform
for the rational design of inhibitors for metzincins like BaP1,
TACE, or MMPs.
EXPERIMENTAL PROCEDURES
Protein Purification. BaP1 was isolated from a venom pool
collected from adult specimens of B. asper of the Pacific regions
of Costa Rica. After extraction, venom was lyophilized and
stored at -20 C. BaP1 was purified following established
methods (18, 19). Briefly, initial purification was done via ion-
exchange chromatography on a CM Sephadex C-25 column
(Pharmacia), followed by an affinity chromatography on Affi
Gel Blue column material (Bio-Rad). After BaP1 was judged to
be pure by SDS-PAGE (41), it was either lyophilized or directly
used for assays. For crystallization experiments, lyophilizedBaP1
was diluted in buffer A [15 mM Tris-HCl (pH 8.0) and 200 mM
sodium chloride] and loaded onto a Superdex-200 26/60 column
(Amersham Biosciences) preequilibrated with buffer A. BaP1-
containing fractions were pooled, concentrated, and either
directly used for crystallization experiments or cryocooled in
liquid nitrogen and stored at -80 C.
Protease InhibitionAssays.The proteolytic activity of BaP1
was assayed by unselective cleavage of azocasein (42). Different
concentrations of purified BaP1 were diluted in 20 μL of buffer B
[25 mM Tris-HCl (pH 7.4), 150 mM sodium chloride, and 5 mM
calcium chloride] and were mixed with 100 μL of a solution of 10
mg/mL azocasein in buffer B. After an incubation for 90 min at
37 C, 200 μL of 5% (v/v) trichloroacetic acid was added to
quench the reaction and the samples were centrifuged for 10 min
at 4000g; 100 μL of the supernatant was mixed with an equal
amount of 0.5 M sodium hydroxide, and the absorbance at 450
nm was recorded. For inhibition testing, BaP1 (0.7 mg/mL) was
preincubated for 30 min at 37 Cwith different concentrations of
the inhibitor in buffer B before addition of the azocasein solution.
Assays were performed in triplicate. Statistical analysis and
nonlinear regression were performed using Prism 5.0 (GraphPad
Software, Inc.).
Protein Crystallization. Crystals of BaP1 were obtained via
hanging-drop vapor diffusion at 21 C. BaP1 3 inhibitor com-
plexes at pH 4.6, 6.5, and 7.5 were obtained by mixing equal
volumes of a protein solution (5-10 mg/mL) containing 880 μM
inhibitorwith the following reservoir solutions: crystal I (pH 4.6),
100 mM sodium acetate, 30% (w/v) polyethylene glycol 4000,
and 200mMammoniumacetate; crystal II (pH6.5), 100mMTris
and 30% (w/v) polyethylene glycol 20000; crystal III (pH 7.5),
100 mM HEPES, 20% (w/v) polyethylene glycol 3000, and 200
mM sodium chloride. Crystals grew within a few days as thin
plates, all belonging to orthorhombic space group P212121.
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To obtain the inhibitor complex at pH 8.0 (crystal IV), a native
crystal grown in 100 mM imidazole (pH 8.0) and 10% (w/v)
polyethylene glycol 8000 was placed into a drop containing 3.0
mg/mL BaP1 and 550 μM inhibitor in the same buffer and
equilibrated for 70 h. All crystals were cryoprotected in their
respective reservoir solutions containing 10% (v/v) glycerol and
flash-frozen in liquid nitrogen.
Data Collection, Model Building, and Refinement. Na-
tive data sets were collected at 100 K and a wavelength of 0.92 A˚
at beamline BL14.1 at BESSY (Berliner Elektronenspeicherring-
Gesellschaft fur Synchrotronstrahlungm.b.H., Berlin,Germany)
(Table 1). Diffraction data were processed and scaled using XDS
and XSCALE (43). Because the BaP1 3 inhibitor crystals in this
study were isomorphous to previously reported native BaP1
crystals (24), the structures of the inhibitor complexes were
determined using difference Fourier methods. Initial electron
density maps were obtained after rigid body refinement with
REFMAC (44) using the unliganded BaP1 structure (PDB entry
1ND1) (24) as a startingmodel. After rebuilding withCOOT (45)
and refinement withREFMAC, the inhibitors weremodeled into
the resulting (Fo - Fc) difference electron density maps. An
energy-minimized conformation of the inhibitor and the corre-
sponding dictionary files were generated with PRODRG2 (46).
Water molecules were placed with ARP/wARP (47) and checked
with COOT. The model was refined using isotropic temperature
factors for data set II and anisotropic temperature factors for the
other data sets (Table 2). The atoms of the loop region between
residues 159 and 162 were modeled with half-occupancy con-
cerning to the two conformations of the loop. All figures were
produced with MOLSCRIPT and POVScript+ (48, 49).
RESULTS AND DISCUSSION
Crystals of BaP1 in complex with a hydroxamate inhibitor
were obtained at four different pH values, and the structures were
determined to atomic resolution (Tables 1 and 2). The structures
of the inhibitor complex were determined by difference Fourier
methods using the structure of native BaP1 (24). Because there
were no significant conformational changes between the four
structures, the following discussion will refer to the 1.08 A˚
structure obtained at pH 8.0 (data set IV), unless stated other-
wise. During structure analysis, it became clear that residue 151,
originally reported to be an aspartate due to poor electron
density, is in fact a histidine.
In the BaP1 3 inhibitor structure, all residues are well-defined in
the electron density, with the exception of a few amino acids with
disordered side chains at the protein surface. The electron density
for the inhibitor was continuous at the 3σ contour level and
allowed unambiguous placement of its scaffold (Figure 1A). In all
four crystal structures, an additional glycerol molecule from the
cryoprotectant was identified near the active site, which is held
into place by hydrogen bonds to the Nε atom of Arg110, a water
molecule, and the inhibitor. A loop segment containing residues
159-162 existed in a double conformation in all four crystals and
was modeled as such.
Interaction between BaP1 and the Inhibitor. The synthetic
hydroxamate derivative used in this study inhibited BaP1 with an
IC50 value of 22.2 μM (Figure 2). This peptidomimetic was
originally designed as a TACE inhibitor (personal communica-
tion, Roche Pharmaceutics). Due to the fact that TACE and
BaP1 have structurally very similar binding sites, it was then used
to analyze its effects on snake venom metalloproteinases. In the
structure, the hydroxamate derivative occupies the peptide bind-
ing cleft of BaP1, forming interactions over its entire length. As
points of reference, the peptidomimetic inhibitor can be sepa-
rated into four parts (Figure 3). In the following, functional
groups, namely, hydroxamate (Hyd1), isobutyl (Byl2), tert-butyl
(Byl3), and methyl (Myl4), are used to identify the different parts
of the inhibitor. The N-methylthiazole-2-carboxamide group of
Byl2 is shortened to thiazole. Following common nomenclature
for peptide/protease complexes, these groups are divided into P1
(thiazole), P10 (Byl2), P20 (Byl3), and P30 (Myl4). In its binding
mode, the inhibitor closely mimics the C-terminal part of an
enzyme-bound peptide substrate. It is held in position by hydro-
gen bonds and van der Waals contacts involving its backbone
and side chains as well as a cation-π interaction (Figure 4). The
hydrogen bonding network between the enzyme and inhibitor
backbone resembles that of an antiparallel β-sheet.
Four regions of BaP1 are involved in inhibitor binding. The
first consists of part of strand β4 and the proceeding loop. The
second is the zinc binding motif, which contains part of helix R4
and the following loop. The third region is part of the loop
connecting helices R4 and R5. The fourth is residue Thr139
(Figure 4). These determinants cover four binding subsites of
BaP1, one on the N-terminal side of the catalytic center (S1) and
three on the C-terminal side (S10, S20, and S30) (Figure 1B).
The first segment (Asn106-Thr107-Ile108-Gly109-Arg110)
contributes to all peptide-binding subsites of BaP1. Thr107 and
Arg110 are involved in forming subsite S1, Thr107 and Ile108 in
subsite S10, Asn106 and Thr107 in subsite S20, and Asn106 and
Ile108 in subsite S30. As the first segment is part of strand β4,
hydrogen bonding is dominated by backbone interactions, with
bonds formed between the main chainO atom ofAsn106 and the
N atom ofMyl4, between theN atomof Ile108 and theO atom of
Byl2, and between the O atom of Gly109 and the amide nitrogen
of Hyd1 (Figure 4). These main chain interactions are the reason
for the observed 1.4 A˚ shift of the loop segment toward the
inhibitor upon binding. Additionally, there are side chain hydro-
gen bonds between the Oδ atom of Asn106 and the N atom of
Myl4 as well as between the Oγ atom of Thr107 and the O atom
of P1. Whereas the Thr107 side chain only slightly changes its
orientation, the Asn106 side chain, which is solvent-exposed in
the native structure, now points toward the inhibitor (Figure 4).
Ile108 is part of the entrance of the S10 subsite tunnel, which is
known for its high hydrophobicity in all SVMPs and is likely to
be responsible for substrate specificity (4, 24). Its Cγ and Cδ
atoms are within van der Waals contact distance of the C atoms
of P10 (3.8 A˚). Thr139 is also part of the S10 subsite tunnel
entrance, and its Cγ atom, as well as that of Thr107, is within
hydrophobic contact distance of the inhibitor’s P10 residue
(Figure 4).
A rarely seen type of inhibitor-enzyme interaction is observed
between the Arg110 side chain (subsite S1) and the P1 residue of
the peptidomimetic scaffold, as they forma cation-π interaction.
The delocalized positive charge of the arginine side chain inter-
acts with the π-system of the thiazole ring. In the native structure
of BaP1, Arg110 extends into the bulk solvent, hence increasing
the height of the docking site wall (Figure 1B). Interestingly, in
the BaP1 3 inhibitor complex, it is flipped toward helix R3,
forming a hydrogen bond with the Ser72 side chain (not shown)
and placing the positive charge within contact distance of the ring
of P1 (Figure 4). The observed distances (3.5-3.7 A˚) betweenNη
and Nε atoms of Arg110 and the plane of the aromatic thiazole
ring of P1 are close to the energetically most favorable distance
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(4.0 A˚) for this kind of interaction. The P1 residue is also fixed by
a hydrophobic interaction with the Cγ atom (Figure 4).
The only amino acid of the zinc binding motif (ranging from
His142 to Asp153) involved in BaP1 subsite building is His142. It
is also part of the entrance of the S10 pocket and thus interacting
with residue P10 (Cγ andCε atoms). On its other side (Nε2 atom),
it is involved in coordination of the zinc ion (Figure 4). As has
been observed in the majority of 4-fold zinc coordination systems
in enzymes, the zinc ion is tetrahedrally coordinated by the Nε2
atoms of three histidines (His142, His146, and His152) and a
catalytic water molecule in the noncomplexed BaP1 structure
(Figure 5A) (24, 50). In contrast, the zinc ion in the inhibitor
complex is 5-fold coordinated, with nearly perfect square pyr-
amidal coordination geometry (Figure 5B). The Nε2 atoms of
His146 and His152 and both oxygens of Hyd1 form the basal
plane of the pyramid, and the Nε2 atom of His142 is the apex.
The zinc ion is slightly displaced toward the apex, out of the plane
of the basal atoms. Compared with the more common trigonal
bipyramidal geometry, this square pyramidal arrangement is
rarely observed in five-coordinate enzymatic zinc centers (26% vs
74%) (50).
The binding of the inhibitor results in the displacement of
several watermolecules at the docking site of native BaP1, i.e., the
catalytic Wat67. Wat67 has been proposed to play a critical role
as the catalytic nucleophile in SVMPs, attacking the scissile
peptide bond after polarization by the highly conserved
Glu143 (24). Only two water molecules, Wat7 and Wat13 deep
inside the S10 pocket, were found near the active site in the
inhibitor complex. Wat7 interacts with the backbone O atoms of
Ile165 and Ala167 andWat13 with the backbone N andO atoms
of Ser171 as well as with the Ser163 side chain. Instead of
coordinating the catalytic watermolecule, Glu143 rotates toward
the hydroxamate group (Hyd1) of the inhibitor and forms
hydrogen bonds with it (Figure 4). The glycerol O3 atom is
detected close to the original position of another water molecule
in the native structure (Wat69).
Backbone atoms of the last segment (Ser168-Val169-Leu170)
are the main part of the S10 and S20 subsites of BaP1, interacting
with the inhibitor scaffold via two hydrogen bonds. The first is
formed by the backbone O atom of Ser168 with the backbone N
atom of Byl3 and the second between theO atom of Byl3 with the
main chain N atom of Leu170. Presumably, these interactions
force this loop segment on a 1.3 A˚ shift toward the inhibitor upon
binding. This could also be the reason for the rotamer change of
the Ser168 side chain, although it is not directly involved in
inhibitor binding (Figure 4). Besides the hydrogen bonds, almost
all main chain atoms of the loop arewithin van derWaals contact
distance of the inhibitor P10 residue. Additionally, the side chain
atoms of Val169 are possible interaction partners for the P20
inhibitor residue, which points outside the cleft toward the bulk
solvent. The Cγ atoms of Val169 are located close (3.8 and 4.2 A˚)
to one of the methyl groups of P20, which probably imposes the
Val167 side chain on a 90 rotation (Figure 4). Because the side
chain of Leu170 is positioned alongside the binding site cleft, it
interacts with the P10 residue as well as with the P30 residue and is
part of two different subsites (S10 and S30).
Overall, inhibitor binding affects only the substrate bind-
ing pocket, while the rest of the protease is unperturbed. Inhibitor
binding causes the pocket-flanking loops to shift inward by
2.7 A˚, narrowing the substrate binding cleft. The most obvious
differences occur at residues Asn106, Arg110, and Val169, which
Table 1: Data Collection Statistics
I II III IV
space group P212121 P212121 P212121 P212121
wavelength (A˚) 0.91841 0.91841 0.91841 0.91841
resolution range (A˚)a 20.0-1.14 (1.21-1.14) 19.3-1.46 (1.55-1.46) 20.0-1.05 (1.11-1.05) 20.0-1.08 (1.11-1.08)
cell parameters a, b, c (A˚) 38.1, 59.6, 82.7 38.0, 59.5, 81.8 37.9, 59.8, 83.3 37.9, 59.8, 83.1
no. of unique reflectionsa 68715 (10292) 32970 (4755) 84722 (10797) 77288 (4106)
completeness (%)a 98.7 (93.0) 98.4 (90.1) 95.0 (75.9) 94.6 (64.6)
multiplicity of observations 6.9 7.0 7.6 7.4
I/σ(I)a 18.8 (5.4) 21.9 (6.7) 25.2 (7.8) 17.6 (4.2)
Rmeas (%)
a 7.9 (38.0) 6.7 (28.0) 5.6 (24.1) 7.2 (38.1)
Rsym (%)
a 7.3 (34.4) 6.2 (25.4) 5.2 (21.7) 6.7 (33.4)
Wilson B (A˚2) 9.0 8.7 10.1 8.7
VM (A˚
3 Da-1) 2.07 2.03 2.08 2.07
solvent content (%) 40.5 40.0 40.8 40.7
aData in the highest-resolution shell are given in parentheses.
Table 2: Refinement and Model Quality
I II III IV
resolution range (A˚) 18.2-1.14 17.8-1.46 19.7-1.05 18.2-1.08
no. of unique reflections 66242 32627 82161 74965
no. of reflections in test seta 2403 (3.5) 1631 (5.0) 2542 (3.0) 2318 (3.0)
Rcryst (%)
b 13.0 14.8 11.7 11.8
Rfree (%)
b 16.0 17.8 14.4 14.3
no. of atoms
protein 1747 1657 1698 1702
water molecules 345 376 391 370
ligands 51 37 37 42
total 2143 2070 2126 2114
B-factor (A˚2)
main chain 5.6 6.2 5.3 6.0
side chain 8.0 9.0 8.1 8.7
ligands 10.3 8.2 8.2 8.0
water molecules 20.4 22.2 19.8 20.5
total 9.1 10.3 9.1 9.8
rms deviationsb
bond lengths (A˚) 0.016 0.018 0.017 0.017
bond angles (deg) 1.776 1.861 1.793 1.748
Ramachandran statistics (%)c
favored region 98.0 98.5 98.5 99.0
allowed region 2.0 1.5 1.5 1.0
outlier region 0.0 0.0 0.0 0.0
aThe percentage of reflections in the test set is given in parentheses.
b R-Factors and rms deviations after the last refinement step with RE-
FMAC (44). cRamachandran statistics calculated with RAMPAGE (53).
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FIGURE 1: Stereoviews of the inhibitor bound to the snake venom metalloproteinase BaP1. (A) Ribbon plot of BaP1 with the initial (Fo - Fc)
electron density map of the inhibitor at a contour level of 3σ. The final model of the inhibitor is drawn into the density. The six cysteine residues
involved in disulfide bonding and the conservedMet turnwith themethionine residue are indicated for reference. The catalytic zinc ion is shown as
amagenta sphere. (B) Inhibitor sitting in the shallow binding cleft of BaP1 represented by itsmolecular surface. TheN-terminus of enzyme-bound
substratewouldbe located on the left and theC-terminus on the right.The zinc ion, the coordinating histidine residues, and the ribbonplot ofBaP1
are shownbeneath the surface. Involvedbinding subsites ofBaP1are denotedwithblack labels and secondary structure elementswithwhite labels.
FIGURE 2: Inhibitory effect of the hydroxamate derivative on the
proteolytic activity of BaP1. Sigmoidal dose-response curve as a
semilog plot of the inhibitor concentration and the relative inhibition
of the proteolytic activity ofBaP1.Activity testingwas determinedon
the basis of unselective cleavage of azocasein. Statistical analysis and
nonlinear regression were performed with Prism 5.0 (GraphPad
Software, Inc.) and led to an IC50 value of 22.2 μM (95% confidence
interval, 21.5-23.0 μM). Data are expressed as means ( standard
deviations of the relative inhibition.
FIGURE 3: Schematic structure of the peptidomimetic inhibitor. Its
functional groups (hydroxamate, isobutyl, tert-butyl, andmethyl) are
used for abbreviation and fragmentation of the scaffold (Hyd1, Byl2,
Byl3, and Myl4). The N-methylthiazole-2-carboxamide group of
Byl2 is shortened to thiazole. Inhibitor residues P1-P30 and enzy-
matic subsites involved in binding are indicated.
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bind the inhibitor directly and change rotamers (Figure 4). This
flexibility at the binding pocket is in agreement with the broad
substrate specificity seen in SVMPs, making BaP1 well suited to
cleave a variety of peptides in the extracellular matrix.
Zinc Coordination Geometry and pH Dependency of
Proteolytic Activity. The catalytic zinc ion in BaP1 changes
its coordination geometry from four-coordinate tetrahedral in
the unliganded native state to five-coordinate square pyramidal
in the inhibitor complex (Figure 5 and Table 3). Such an
expansion is expected to result in longer zinc coordination
distances (50). However, this is only the case for His152 (2.063 (
0.009 A˚ for the Zn-Nε2 distance vs 2.0 A˚ in the native
structure). The corresponding distance to His142 remains equal
(2.048 ( 0.011 A˚ vs 2.05 A˚), while the one to His146 even
decreases (2.048 ( 0.005 A˚ vs 2.12 A˚).
For SVMPs, it has been suggested that proteolytic activity
depends on the protonation state of the zinc-coordinating
histidine residues on one hand and on the polarization capacity
of the glutamate residue on the other (4). In a study on acutolysin
C using X-ray absorption near-edge structure spectroscopy
(XANES) at different pH values, it was shown that with a
change in pH from 8.0 to 3.0 the overall arrangement of the
catalytic zinc ion remained tetrahedral, but the zinc coordination
distances and the distance between the glutamate and the active
site water molecule increased (51). In a similar vein, pH-depen-
dent changes in the protonation state of the active site histidines
have been proposed to cause a change in zinc coordination
distances (35). To address this question, we performed an
additional step of refinement with REFMAC in which all
metal-ligand restraints had been removed. Subsequent analysis
of the BaP1 3 inhibitor complex at four different pH values
between 4.6 and 8.0 showed no detectable trend in zinc coordina-
tion (Table 3). All three histidines feature quite similar average
Zn-N distances: 2.048 ( 0.011 A˚ (His142 Nε2 atom), 2.048 (
0.005 A˚ (His146 Nε2 atom), and 2.063 ( 0.009 A˚ (His152 Nε2
atom). Standard deviations are calculated between the four
presented structures and are all within coordinate error (0.025
A˚ for data set IV). Likewise, there is no significant change in the
FIGURE 4: Stereoview of the BaP1 active site with the bound inhibitor as a stick model. Carbon atoms are colored gray (BaP1) and orange
(inhibitor), oxygen atoms red, nitrogen atoms blue, and sulfur atoms yellow, and the catalytical zinc ion is shown as amagenta sphere. Important
interactions are indicated as follows: hydrogen bonds as black dashed lines, zinc coordination as magenta dashed lines, hydrophobic contacts as
green dots, and cation-π interaction as purple dots. All enzymatic and inhibitor residues are indicated, and the complexed glycerol molecule is
labeled with GOL. Side chains of Asp106, Arg110, Glu143, Ser168, and Val169 of noncomplexed BaP1 are shown as black sticks.
FIGURE 5: Zinc coordination sphere of noncomplexed and inhibitor-
bound BaP1. (A) Noncomplexed BaP1. The zinc ion is coordinated
tetrahedrally by the Nε2 atoms of three histidine residues (H142,
H146, and H152) and the oxygen atom of the catalytical water
molecule (Wat67). Carbon atoms are shown as gray and nitrogen
atoms asblue sticks. Thewatermolecule is represented as a red sphere
and the zinc ion as a magenta sphere. Coordination distances are all
given in angstroms and taken from PDB entry 1ND1 (24). (B) BaP1
with the complexed inhibitor (only Hyd1 is depicted). The zinc ion is
coordinated in a nearly perfect square-based pyramidal geometry by
the Nε2 atoms of three histidine residues (H142, H146, and H152)
and both oxygen atoms of Hyd1. The latter atoms and those of
His146 andHis152 form the basal plane of the pyramid, and the Nε2
atom of His142 is the apex. Carbon atoms are shown as gray,
nitrogen atoms as blue, and oxygen atoms as red sticks, and the zinc
ion is represented as a magenta sphere. Coordination distances are
given in angstroms and represent the average values of all four
presented structures.
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distances between the zinc ion and the hydroxylic Hyd1(OH) and
carboxylicHyd1(O) oxygen atoms of the inhibitor (2.230( 0.004
and 2.018 ( 0.005 A˚, respectively).
Asmentioned above, it is generally accepted that the conserved
glutamate residue plays an important role in acting as a general
base during the reactionmechanism of metzincins (3). During the
first step (addition), the catalytic water molecule is deprotonated,
allowing its nucleophilic attack at the carbon atom of the peptide
bond. This causes a tetrahedral reaction intermediate and a
protonated glutamate residue. During the second step (elimina-
tion), the proton is transferred to the N-terminus of the cleaved
substrate. Presumably, the proteolytic reaction mechanism is
trapped by the peptidomimetic inhibitor in the transition state of
the reaction. Although the protonation state of the glutamate
residue cannot be determined through a simple X-ray experi-
ment, onemay reasonably assume so, because both oxygen atoms
of the glutamate residue are found to bewithin hydrogen bonding
distance of the hydroxamate group of the inhibitor (Table 3).
Unlike the decreasing distances between the glutamate residue
and the catalytic water molecule in nonliganded SVMPs, no
evidence exists for such a change in the BaP1 3 inhibitor com-
plexes. No significant variation of the corresponding Glu143
(Oε1)-Hyd1(OH) and Glu143(Oε2)-Hyd1(N) distances can be
observed at the different pH values (Table 3). In contrast to
proteolytic activity, this suggests that inhibitor binding does not
seem to be dependent on pH. Nevertheless, conclusions concern-
ing atomic distances should be regarded critically, even though
the estimated overall coordinate errors of the present high-
resolution structures are lower than those of previously available
low-resolution structures (1.8-2.2 A˚) (35).
Another possiblemechanism for pH-dependentmodulation of
proteolytic activity is a more widespread change in enzyme
structure (52). For the BaP1 3 inhibitor complex, there are only
a few side chain and loop shifts, mainly at the protein surface and
the active site, but no significant conformational changes in the
peptide backbone at different pH values can be observed.
Structural alignments lead to CR rms deviations between 0.05
and 0.20 A˚ in pairwise comparisons. Thus, the structures can be
regarded as the same, and our high-resolution analysis does not
support the idea of wide-range conformational shifts causing a
change in activity.
Flexible Loop Region and Its Importance for Hemor-
rhagic Activity. Several investigations have correlated surface
characteristics and structural variations within the family of
SVMPs, especially at a loop region comprising residues 153-
176, with their hemorrhagic potential (24-26). This loop sur-
rounds the active site and contains the highly conservedMet turn
(C164I165M166). It was proposed that this loop, by virtue of its
surface localization and its proximity to the active site, mediates
extracellular matrix substrate binding and thereby influences
the hemorrhagic potential of the enzymes. In our analysis of
BaP1, the first part of the loop (residues 154-162) shows
high flexibility, with considerably higher B-factors (values for
main and side chain atoms of 12.8 and 15.2 A˚2, respectively)
compared to the average values of the whole protein (6.0 and
8.7 A˚2, respectively). The last four residues in this segment
(159-162) are in a double conformation in all four BaP1 3 inhi-
bitor structures, representing a superposition of closed and open
conformations. In the closed conformation, this loop segment
packs against residues 175-177 through backbone interactions,
while it extends into the bulk sovent in the open conformation.
In contrast to this highly flexible segment, the remainder of the
loop region on the C-terminal side of the Met turn is rigid again
(6.6 and 9.1 A˚2, residues 167-176) (Figure 6). A comparison of
the B-factor distribution of identical residues in the noncom-
plexed form of BaP1 shows the same tendencies in flexibility
by the unchanged rigidity of the active site residues (data not
shown).
This observation displays the flexibility of the loop and argues
for its functional relevance.As the catalytic center andother parts
involved in proteolytic activity, like the conserved Met turn, are
not affected by the loop’s conformational change, one can
assume that the protein is capable of varying its surface properties
without influencing its proteolytic activity. Thereby, it would be
enabled to dock to different kind of substrates in the extracellular
Table 3: Coordination Distancesa at the Active Site of Complexed and Noncomplexed BaP1
I, pH 4.6 II, pH 6.5 III, pH 7.5 IV, pH 8.0 BaP1,b pH 9.0
His142(Nε2)-Zn2+ 2.04 2.08 2.03 2.04 2.05
His146(Nε2)-Zn2+ 2.06 2.04 2.05 2.04 2.12
His152(Nε2)-Zn2+ 2.06 2.09 2.05 2.05 2.00
Hyd1(OH)-Zn2+ 2.23 2.23 2.24 2.22 -
Hyd1(O)-Zn2+ 2.01 2.03 2.01 2.02 -
Glu143(Oε1)-Hyd1(OH) 2.62 2.54 2.61 2.67 -
Glu143(Oε2)-Hyd1(N) 3.24 3.23 3.25 3.27 -
Wat67-Zn2+ - - - - 2.25
Glu143(Oε1)-Wat69 - - - - 2.86
Glu143(Oε2)-Wat67 - - - - 3.01
aAll coordination distances are given in angstroms. bData taken from the noncomplexed structure of BaP1 (PDB entry 1ND1) (24).
FIGURE 6: B-Factor plot of the flexible loop region (residues 152-
176). For reference, the average B-factor of all BaP1 CR atoms
(6.01 A˚2) is indicated as a dotted line.
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matrix and nevertheless restore its functionality as a peptide-
cleaving enzyme.
CONCLUSIONS
Metzincins play an important role in many diseases affecting
humans. However, effective and selective drugs against metallo-
proteinases are still rare. There is no neutralizing drug against the
local pathological effects caused by snake bites, and in spite of
massive research, only a few inhibitors against human ADAMs
and MMPs have passed clinical trials. In the majority of cases,
these small molecule inhibitors contain a zinc-binding group
(ZBG), a peptide backbone or peptidomimetic scaffold, and
suitable side chains that bind to the enzymatic subsites. Because
metalloproteinases often cleave a wide range of targets, they are
quite flexible in binding peptides and display broad substrate
specificity. Thus, developing highly selective metalloproteinase
inhibitors still poses one of the main challenges in the search for
successful clinical candidates. To that end, three-dimensional
structures of metalloproteinase-inhibitor complexes present
crucial information about the structural determinants of sub-
strate selectivity.
The BaP1 3 inhibitor complex reported here contributes to
metalloproteinase crystal structures with one of the best resolu-
tion ranges ever obtained. Despite the moderate IC50 value of the
inhibitor, the high-resolution structure is an excellent starting
point for further optimization. The atomic detail offers insight
into inhibitor binding and the structural determinants for pro-
teolytic activity. In particular, the deep tunnel-like S10 subpocket
of BaP1 suggests the inhibitor might be improved by using a
longer residue at the P10 position. Because of the poor bioavail-
ability of hydroxamate derivatives, a change of the ZBG might
also be considered.
The finding about the flexible loop region, which is possibly
correlating with hemorrhagic activity, has a great impact
on further studies, as to date only little about hemorrhagic
activity and its structural and sequential dependencies is known.
More detailed insight into structural requirements for the hemor-
rhagic potential of snake venoms will be helpful for the local
therapy of snake venom poisonings. A comparison of the BaP1 3
inhibitor complex with human metalloproteinases reveals simi-
larities in terms of not only the overall protein structure but also
specifically the shape and properties of the binding site. Accord-
ingly, the reported inhibitor, which was primarily designed as a
TACE inhibitor, is significantly blocking the activity of BaP1,
thus confirming the similarities in the arrangement and mode of
action of the catalytic domains. This highlights BaP1, whose
isolation from snake venom is straightforward, as amodel system
not only for SVMPs but also for relevant medicinal, human
metalloproteinase targets.
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